All GLG News Analyses Filed Under: Infectious Disease

Peter BornsteinPartner and Consultant in Infectious DiseasesSt. Paul Infectious Disease Associates, Ltd

Better Tuberculosis vaccine is desperately needed, but will a vaccinia-based vaccine be safe and embraced?

April 23, 2009

Analysis of:TB vaccine enters advanced clinical trials at Oxford | timesofindia.indiatimes.com

The decades old BCG vaccine needs to be replaced.  It offers at best 50% efficacy, can at times cause severe reaction, and renders subsequent tracking of active TB difficult to impossible. This article describes a trial in South Africa to assess the effectiveness of a new candidate vaccine in infants already immunized with BCG. There is a significant reason why there are so few specifics in the press release.

Promising Idea

April 23, 2009

Analysis by: GLG Expert Contributor

Analysis of:TB vaccine enters advanced clinical trials at Oxford | timesofindia.indiatimes.com

With the epidemic and endemic nature of TB throughout the entire world, a vaccine with good safety and efficacy would be a tremendous advance. BCG is in wide use, but has limited efficacy.    

Novagali Phase II Results are Cyclokat (R) for Dry Eye Promising

April 17, 2009

Analysis by: GLG Expert Contributor

Analysis of:Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry Eye | www.pipelinereview.com

Promising results from Novagali's phase II study of their novel product Cyclokat is very promising for the moderate to severe dry eye patient.  Once a day dosing is a real plus. 

Frank MalinoskiPresidentTD Consultancy, LLC

Third Generation Pneumococcal Vaccine

April 14, 2009

Analysis of:Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children | phx.corporate-ir.net

1.  Broader coverage to further reduce pneumococcal disease burden, especially in countries with higher proportion of the 6 new serotypes in the 13 valent product. 2.  Gives Wyeth continued competitive advantage as no other 13 valent ready for approval. 3.  Will canabalize existing sales of 7 valent (Prevenar) but will expand use in other markets because of better serotype coverage.

Robert BoorsteinAssociate Professor, PathologyNEW YORK UNIVERSITY (INC)

Potential markets for new Roche MRSA test

April 13, 2009

Analysis of:New advanced MRSA test in the EU | www.ptemag.com

Roche has now received CE approval for its MRSA test using real time PCR methodology.  As one of the largest clinical molecular diagnostics companies, Roche clearly is trying to expand its menus and its markets, and build on its installed base.  This product is not yet available in the US.  This product will compete with existing offerings from Becton-Dickinson and with Cepheid. 

Roche's real-time PCR for MRSA needs clinical tests

April 9, 2009

Analysis by: GLG Expert Contributor

Analysis of:New advanced MRSA test in the EU | www.ptemag.com

Roche's LightCycler 2.0 real-time PCR for MRSA will need further validation from designed quality control testing by unbiased clinical diagnostic laboratories.  Provided the new test procedure for MRSA meets the criteria for accuracy, then, clinical tests could prove useful to evaluate the epidemiology of MRSA in various situations. 

Glen McDanielPresident and Chief Executive OfficerGM Global

Roche adds to anti-MRSA arsenal in Europe

April 8, 2009

Analysis of:Roche introduces new LightCycler MRSA advanced test in EU | www.roche.com

European healthcare organizations have always been more aggressive in identifying MRSA infections. Europe popularized the "search and destroy" protocol of MRSA containment. This new method by Roche is a valuable addition in this arsenal. I expect the LightCycler MRSA Test by Roche to be popular and very lucrative for Roche.

Peter BornsteinPartner and Consultant in Infectious DiseasesSt. Paul Infectious Disease Associates, Ltd

Safety profile similar to placebo! Can't do better than that.

April 6, 2009

Analysis of:Intercell announces European approval of new vaccine, IXIARO®, to prevent Japanese Encephalitis | www.pipelinereview.com

Intercell vaccine is as effective as current JE-VAX, with side-effects similar to placebo. The current JE-VAX is used parsimoniously because of the risk of hypersensitivity reactions. This new vaccine will likely supplant and replace the current vaccine. However, until it has US approval, there may not be recommendations from CDC regarding its use.

Gardasil for boys? If you're not kidding, at least make it about science this time.

March 30, 2009

Analysis by: GLG Expert Contributor

Analysis of:A Vaccine Debate Once Focused on Sex Shifts as Boys Join the Target Market | www.washingtonpost.com

HPV vaccination in females makes sense from a moral and medical point of view, and may even be cost-effective in the long run.   HPV vaccination in males is none of these.

HPV vaccine for males

March 30, 2009

Analysis by: GLG Expert Contributor

Analysis of:A Vaccine Debate Once Focused on Sex Shifts as Boys Join the Target Market | www.washingtonpost.com

The HPV vaccine has been approved for and is currently being administered to female patients.  Males also acquire and transmit the HPV virus but, until now, do not receive the preventative vaccine.

Previous Page : 12345678910Next41 to 50 of 362